Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction
© 2020 Elsevier B.V. Background: Dapagliflozin is an antidiabetic medication that has been shown to reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF). This study aimed to determine the cost-utility of add-o...
Saved in:
| Main Authors: | , |
|---|---|
| 格式: | 雜誌 |
| 出版: |
2020
|
| 主題: | |
| 在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089826614&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70945 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
成為第一個發表評論!